
CLAIMS

1. A compound of formula I:



(I)

or a pharmaceutically acceptable derivatives thereof, where

X is O, S, N-CN, N-OH, or N-OR_{10};


W is N or C;

the dashed line denotes the presence or absence of a bond, and when the dashed line denotes the presence of a bond or W is N then R_4 is absent, otherwise R_4 is -H, -OH, $-OCF_3$, -halo, -(C_1-C_6)alkyl, $-CH_2OH$, $-CH_2Cl$, $-CH_2Br$, $-CH_2I$, $-CH_2F$, $-CH(halo)_2$, $-CF_3$, $-OR_{10}$, $-SR_{10}$, -COOH, $-COOR_{10}$, $-C(O)R_{10}$, -C(O)H, $-OC(O)R_{10}$, $-OC(O)NHR_{10}$, $-NHC(O)R_{13}$, $-CON(R_{13})_2$, $-S(O)_2R_{10}$, or $-NO_2$;


R_{10} is -(C_1-C_4)alkyl;

each R_{13} is independently -H, -(C_1-C_4)alkyl, -(C_1-C_4)alkenyl, -(C_1-C_4)alkynyl, or –phenyl;

Ar_1 is



Ar_2 is



c is the integer 0, 1, or 2;

Y_1, Y_2, Y_3 are independently C, N, or O;

wherein no more than one of Y_1, Y_2, or Y_3 can be O, and for each Y_1, Y_2, and Y_3 that is N, the N is bonded to one R_{21} group, and for each Y_1, Y_2, and Y_3 that is C, the C is bonded to two R_{20} groups, provided that there are no more than a total of two (C_1-C_6)alkyl groups substituted on all of Y_1, Y_2, and Y_3;

R_{12a} and R_{12b} are independently –H or -(C_1-C_6)alkyl;

E is =O, =S, =CH(C_1-C_5)alkyl, =CH(C_1-C_5)alkenyl, -NH(C_1-C_6)alkyl, or =N-OR_{20};


R_1 is -H, -halo, -(C_1-C_4)alkyl, -NO_2, -CN, -OH, -OCH_3, -NH_2, -C(halo)$_3$, -CH(halo)$_2$, -CH_2(halo), -OC(halo)$_3$, -OCH(halo)$_2$, or -OCH_2(halo);

each R_2 is independently:

(a) -halo, -OH, -O(C_1-C_4)alkyl, -CN, -NO_2, -NH_2, -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, –phenyl, or

(b) a group of formula Q;

wherein Q is



;

Z_1 is -H, -OR_7, -SR_7, -CH_2-OR_7, -CH_2-SR_7, -CH_2-N(R_{20})$_2$, or -halo;

Z_2 is -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -CH_2-OR_7, -phenyl, or -halo;

each Z_3 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, or -phenyl;

Z_4 is –H, -OH, -OR_{20}, -(C_1-C_6)alkyl, or –N(R_{20})$_2$;

J is -OR_{20}, -SR_{20}, -N(R_{20})$_2$, or –CN;


provided that at least one R_2 group is a group of formula Q, and provided that when Z_1 is $-OR_7$ or $-SR_7$, then Z_2 is not –halo;

each R_3 is independently:


(a) –H, $(C_1\text{-}C_6)$alkyl, or CH_2OR_7; or

(b) two R_3 groups together form a $(C_2\text{-}C_6)$bridge, which is unsubstituted or substituted with 1, 2 or 3 independently selected R_8 groups, and which bridge optionally contains -HC=CH- within the $(C_2\text{-}C_6)$bridge; or

(c) two R_3 groups together form a $-CH_2\text{-}N(R_a)\text{-}CH_2-$ bridge, a



bridge, or a



bridge;

R_a is selected from -H, $-(C_1\text{-}C_6)$alkyl, $-(C_3\text{-}C_8)$cycloalkyl, $-CH_2\text{-}C(O)\text{-}R_c$, $-(CH_2)\text{-}C(O)\text{-}OR_c$, $-(CH_2)\text{-}C(O)\text{-}N(R_c)_2$, $-(CH_2)_2\text{-}O\text{-}R_c$, $-(CH_2)_2\text{-}S(O)_2\text{-}N(R_c)_2$, or $-(CH_2)_2\text{-}N(R_c)S(O)_2\text{-}R_c$;

R_b is selected from:

(a) -H, $-(C_1\text{-}C_6)$alkyl, $-(C_3\text{-}C_8)$cycloalkyl, -(3- to 7-membered)heterocycle, $-N(R_c)_2$, $-N(R_c)\text{-}(C_3\text{-}C_8)$cycloalkyl, or $-N(R_c)$-(3- to 7-membered)heterocycle; or

(b) –phenyl, -(5- or 6-membered)heteroaryl, $-N(R_c)$-phenyl, or $-N(R_c)$-(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with 1, 2 or 3 independently selected R_7 groups;

each R_c is independently selected from -H or $-(C_1\text{-}C_4)$alkyl;

each R_7 is independently -H, $-(C_1\text{-}C_6)$alkyl, $-(C_2\text{-}C_6)$alkenyl, $-(C_2\text{-}C_6)$alkynyl, $-(C_3\text{-}C_8)$cycloalkyl, $-(C_5\text{-}C_8)$cycloalkenyl, -phenyl, $-(C_1\text{-}C_6)$haloalkyl, $-(C_1\text{-}C_6)$hydroxyalkyl, $-(C_1\text{-}C_6)$alkoxy$(C_1\text{-}C_6)$alkyl, $-(C_1\text{-}C_6)$alkyl-$N(R_{20})_2$, or $-CON(R_{20})_2$;

each R_8 and R_9 is independently:

(a) $-(C_1\text{-}C_6)$alkyl, $-(C_2\text{-}C_6)$alkenyl, $-(C_2\text{-}C_6)$alkynyl, $-(C_3\text{-}C_8)$cycloalkyl, $-(C_5\text{-}C_8)$cycloalkenyl, or –phenyl, each of which is unsubstituted or substituted with 1 or 2 –OH groups; or

(b) -H, $-CH_2C(halo)_3$, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, $-OC(halo)_3$, $-OCH(halo)_2$, $-OCH_2(halo)$, $-SC(halo)_3$, $-SCH(halo)_2$, $-SCH_2(halo)$, -CN, -O-CN, -OH,


-halo, $-N_3$, $-NO_2$, $-CH=NR_7$, $-N(R_7)_2$, $-NR_7OH$, $-OR_7$, $-C(O)R_7$, $-C(O)OR_7$, $-OC(O)R_7$, $-OC(O)OR_7$, $-SR_7$, $-S(O)R_7$, or $-S(O)_2R_7$;

each R_{11} is independently -CN, -OH, $-(C_1-C_6)$alkyl, $-(C_2-C_6)$alkenyl, -halo, $-N_3$, $-NO_2$, $-N(R_7)_2$, $-CH=NR_7$, $-NR_7OH$, $-OR_7$, $-C(O)R_7$, $-C(O)OR_7$, $-OC(O)R_7$, or $-OC(O)OR_7$;

each R_{14} is independently –H, $-(C_1-C_6)$alkyl, $-(C_2-C_6)$alkenyl, $-(C_2-C_6)$alkynyl, $-(C_3-C_8)$cycloalkyl, $-(C_5-C_8)$cycloalkenyl, $-(C_1-C_6)$alkoxy-(C_1-C_6)alkyl, -phenyl, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, -(3- to 7-membered)heterocycle, $-(C_1-C_6)$haloalkyl, $-(C_2-C_6)$haloalkenyl, $-(C_2-C_6)$haloalkynyl, $-(C_2-C_6)$hydroxyalkenyl, $-(C_2-C_6)$hydroxyalkynyl, $-(C_1-C_6)$alkoxy(C_2-C_6)alkyl, $-(C_1-C_6)$alkoxy(C_2-C_6)alkenyl, $-(C_1-C_6)$alkoxy(C_2-C_6)alkynyl, $-(C_1-C_6)$alkoxy(C_3-C_8)cycloalkyl, -CN, -OH, -halo, $-OC(halo)_3$, $-N_3$, $-NO_2$, $-CH=NR_7$, $-N(R_7)_2$, $-NR_7OH$, $-OR_7$, $-SR_7$, $-O(CH_2)_bOR_7$, $-O(CH_2)_bSR_7$, $-O(CH_2)_bN(R_7)_2$, $-N(R_7)(CH_2)_bOR_7$, $-N(R_7)(CH_2)_bSR_7$, $-N(R_7)(CH_2)_bN(R_7)_2$, $-N(R_7)COR_7$, $-C(O)R_7$, $-C(O)OR_7$, $-OC(O)R_7$, $-OC(O)OR_7$, $-S(O)R_7$, or $-S(O)_2R_7$, $-S(O)_2N(R_7)_2$, $-SO_2C(halo)_3$, $-SO_2$(3- to 7-membered)heterocycle, $-CON(R_7)_2$, $-(C_1-C_5)$alkyl-C=NOR$_7$, $-(C_1-C_5)$alkyl-C(O)-N$(R_7)_2$, $-(C_1-C_6)$alkyl-$NHSO_2N(R_7)_2$, or $-(C_1-C_6)$alkyl-C(=NH)-N$(R_7)_2$;

each R_{20} is independently –H, $-(C_1-C_6)$alkyl, or $-(C_3-C_8)$cycloalkyl;

each R_{21} is independently –H, $-(C_1-C_6)$alkyl,



;

each halo is independently -F, -Cl, -Br, or -I;

n is the integer 1, 2, or 3;

p is the integer 1 or 2;

each b is independently 1 or 2;

q is the integer 0, 1, 2, 3 or 4;

r is the integer 0, 1, 2, 3, 4, 5, or 6;

s is the integer 0, 1, 2, 3, 4, or 5;

t is the integer 0, 1, 2, or 3; and

m is the integer 0, 1, or 2.

2. The compound of claim 1, wherein X = O.

3. The compound according to any one of claims 1 to 2, wherein R_4 is halo, preferably F.


4. The compound according to any one of claims 1 to 2, wherein R_1 is halo, preferably Cl or F.

5. The compound according to any one of claims 1 to 4, wherein W is C and the dashed line is absent.


6. The compound according to any one of claims 1 to 4, wherein W is C, and the dashed line is a double bond.

7. The compound according to any one of claims 1 to 4, wherein W is N, R_4 is absent and the dashed line is absent.

8. A compound according to any one of claims 1 to 7, wherein Ar_1 is




9. A compound according to any one of claims 1 to 8, wherein the Q-group is selected from



or .

10. A compound according to any one of claims 1 to 9, wherein n is 1, and Q is



11. The compound according to any one of claims 1 to 10, wherein J is selected from OR_{20} or $-N(R_{20})_2$, and preferably is OR_{20} and more preferably is OH.


12. The compound of any one of claims 1 to 11, wherein R_{20} is selected from H or $-(C_1-C_6)$alkyl, and preferably is H.

13. The compound according to any one of claims 1 to 12, wherein Z_3 is independently selected from H or (C_1-C_6)alkyl, and preferably is H.


14. The compound according to any one of claims 1 to 13, wherein Z_1 is H or $-CH_2OR_7$, and preferably is H.

15. The compound according to any one of claims 1 to 14, wherein Z_2 is selected from H, $-(C_1-C_6)$alkyl, or $-CH_2OR_7$, and preferably is H.

16. The compound according to any one of claims 1 to 15, wherein Ar_2 is



17. The compound according to any one of claims 1 to 15, wherein Ar_2 is




and wherein R_{14} is preferably independently selected from halo, $C(halo)_3$, -(C_1-C_6)alkyl, OR_7, $OC(halo)_3$, or $SO_2C(halo)_3$.

18. The compound according to any one of claims 1 to 17, wherein halo is F or Cl.

19. The compound according to any one of claims 1 to 18, wherein s or q is 1 or 2.

20. The compound according to any one of claims 1 to 15, wherein Ar_2 is



and wherein R_8 and R_9 are preferably independently selected from H, halo and -(C_1-C_6)alkyl, and more preferably are H or halo, wherein halo is Cl or F.

21. The compound according to any one of claims 1 to 19, wherein Ar_2 is 2-pyridyl or phenyl, s or q is 1 and the R_{14} substituent is in the 4-position of the Ar_2-substituent.


22. The compound according to any one of claims 1 to 19, wherein Ar_2 is 2-pyridyl or phenyl, s or q is 2 and the R_{14} substituent is in the 3- and 4-position of the Ar_2-substituent.

23. The compound according to any one of the preceding claims, wherein m = 0.

24. The compound according to any one of claims 1 to 22, wherein m = 1 and preferably R_3 is (C_1-C_6)alkyl and more preferably is $-CH_3$ or $-CH_2CH_3$.


25. The compound according to any one of claims 1 to 7 and 23 to 24, wherein Ar_2 is

a)




; or

b)



wherein R_{14} is selected from –H, -Cl, -F, -Br, -OCF_3, -(C_1-C_6)alkyl, SO_2CF_3, SO_2(C_1-C_6)alkyl, -OCH_3, -OCH_2CH_3, -$OCH(CH_3)_2$, and preferably is -CF_3, -OCF_3, -Cl, or –F; or


c)



,


wherein $R_{14'}$ is selected from –H, -Cl, -F, -Br, -OCF_3, -(C_1-C_6)alkyl, SO_2CF_3, SO_2(C_1-C_6)alkyl, -OCH_3, -OCH_2CH_3, -$OCH(CH_3)_2$, and preferably is -CF_3,-OCF_3, -OCH_3, -OCH_2CH_3, -Cl, or –F; or

d)




wherein $R_{14'}$ is selected from –H, -Cl, -F, -Br, $-OCF_3$, $-(C_1-C_6)$alkyl, SO_2CF_3, $SO_2(C_1-C_6)$alkyl, $-OCH_3$, $-OCH_2CH_3$, $-OCH(CH_3)_2$, and preferably is $-CF_3$, $-OCF_3$, OCH_3, OCH_2CH_3, -Cl, or –F; or

e)



; or

f)



wherein each R_8 and R_9 is independently -H, -Cl, -Br, -F, $-CH_3$, $-OCH_3$, $-OCH_2CH_3$, $-CF_3$, $-OCF_3$, *iso*-propyl, or *tert*-butyl.

26. A compound of any one of the preceding claims, wherein the pharmaceutically acceptable derivative is a pharmaceutically acceptable salt.

27. A composition comprising a compound of any one of claims 1 to 26 or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier or excipient.


28. A method of inhibiting TRPV1 function in a cell comprising contacting a cell capable of expressing TRPV1 with an effective amount of a compound of any one of claims 1 to 26 or a pharmaceutically acceptable derivative thereof.

29. A use of a compound according to any one of claims 1 to 26 or a pharmaceutically acceptable derivative thereof in the production of a medicament for the treatment or prevention of pain, UI, an ulcer, IBD, or IBS in an animal.

30. A compound according to any one of claims 1 to 26 for use as a medicament.

CLAIMS:

1. A compound of formula I:



(I)

or a pharmaceutically acceptable derivatives thereof, where

X is O, S, N-CN, N-OH, or N-OR_{10};


W is N or C;

the dashed line denotes the presence or absence of a bond, and when the dashed line denotes the presence of a bond or W is N then R_4 is absent, otherwise R_4 is -H, -OH, -OCF_3, -halo, -(C_1-C_6)alkyl, -CH_2OH, -CH_2Cl, -CH_2Br, -CH_2I, -CH_2F, -CH(halo)$_2$, -CF_3, -OR_{10}, -SR_{10}, -COOH, -$COOR_{10}$, -$C(O)R_{10}$, -C(O)H, -$OC(O)R_{10}$, -$OC(O)NHR_{10}$, -$NHC(O)R_{13}$, -$CON(R_{13})_2$, -$S(O)_2R_{10}$, or -NO_2;


R_{10} is -(C_1-C_4)alkyl;

each R_{13} is independently -H, -(C_1-C_4)alkyl, -(C_1-C_4)alkenyl, -(C_1-C_4)alkynyl, or -phenyl;

Ar_1 is



Ar_2 is



c is the integer 0, 1, or 2;

Y_1, Y_2, Y_3 are independently C, N, or O;

wherein no more than one of Y_1, Y_2, or Y_3 can be O, and for each Y_1, Y_2, and Y_3 that is N, the N is bonded to one R_{21} group, and for each Y_1, Y_2, and Y_3 that is C, the C is bonded to two R_{20} groups, provided that there are no more than a total of two $(C_1\text{-}C_6)$alkyl groups substituted on all of Y_1, Y_2, and Y_3;

R_{12a} and R_{12b} are independently –H or $-(C_1\text{-}C_6)$alkyl;

E is =O, =S, $=CH(C_1\text{-}C_5)$alkyl, $=CH(C_1\text{-}C_5)$alkenyl, $-NH(C_1\text{-}C_6)$alkyl, or $=N\text{-}OR_{20}$;


R_1 is -H, -halo, $-(C_1\text{-}C_4)$alkyl, $-NO_2$, -CN, -OH, $-OCH_3$, $-NH_2$, $-C(halo)_3$, $-CH(halo)_2$, $-CH_2(halo)$, $-OC(halo)_3$, $-OCH(halo)_2$, or $-OCH_2(halo)$;

each R_2 is independently:

(a) -halo, -OH, -O(C_1-C_4)alkyl, -CN, -NO_2, -NH_2, -(C_1-C_{10})alkyl, -(C_2-C_{10})alkenyl, -(C_2-C_{10})alkynyl, –phenyl, or

(b) a group of formula Q;

wherein Q is



;

each Z_3 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, or -phenyl;

J is -OR_{20}, -SR_{20}, -$N(R_{20})_2$, or –CN;


provided that at least one R_2 group is a group of formula Q;

each R_3 is independently:


(a) (C_1-C_6)alkyl, or CH_2OR_7; or

(b) two R_3 groups together form a (C_2-C_6)bridge, which is unsubstituted or substituted with 1, 2 or 3 independently selected R_8 groups, and which bridge optionally contains -HC=CH- within the (C_2-C_6)bridge; or

(c) two R_3 groups together form a -CH_2-N(R_a)-CH_2- bridge, a



bridge, or a



bridge;

R_a is selected from -H, -(C_1-C_6)alkyl, -(C_3-C_8)cycloalkyl, -CH_2-C(O)-R_c, -(CH_2)-C(O)-OR_c, -(CH_2)-C(O)-N(R_c)$_2$, -(CH_2)$_2$-O-R_c, -(CH_2)$_2$-S(O)$_2$-N(R_c)$_2$, or -(CH_2)$_2$-N(R_c)S(O)$_2$-R_c;

R_b is selected from:

(a) -H, -(C_1-C_6)alkyl, -(C_3-C_8)cycloalkyl, -(3- to 7-membered)heterocycle, -$N(R_c)_2$, -$N(R_c)$-(C_3-C_8)cycloalkyl, or -$N(R_c)$-(3- to 7-membered)heterocycle; or

(b) –phenyl, -(5- or 6-membered)heteroaryl, -$N(R_c)$-phenyl, or -$N(R_c)$-(5- to 10-membered)heteroaryl, each of which is unsubstituted or substituted with 1, 2 or 3 independently selected R_7 groups;

each R_c is independently selected from -H or -(C_1-C_4)alkyl;

each R_7 is independently -H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -phenyl, -(C_1-C_6)haloalkyl, -(C_1-C_6)hydroxyalkyl, -(C_1-C_6)alkoxy(C_1-C_6)alkyl, -(C_1-C_6)alkyl-$N(R_{20})_2$, or -$CON(R_{20})_2$;

each R_8 and R_9 is independently:

(a) -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, or –phenyl, each of which is unsubstituted or substituted with 1 or 2 –OH groups; or


(b) -H, -$CH_2C(halo)_3$, -$C(halo)_3$, -$CH(halo)_2$, -$CH_2(halo)$, -$OC(halo)_3$, -$OCH(halo)_2$, -$OCH_2(halo)$, -$SC(halo)_3$, -$SCH(halo)_2$, -$SCH_2(halo)$, -CN, -O-CN, -OH, -halo, -N_3, -NO_2, -$CH{=}NR_7$, -$N(R_7)_2$, -NR_7OH, -OR_7, -$C(O)R_7$, -$C(O)OR_7$, -$OC(O)R_7$, -$OC(O)OR_7$, -SR_7, -$S(O)R_7$, or -$S(O)_2R_7$;

each R_{11} is independently -CN, -OH, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -halo, -N_3, -NO_2, -$N(R_7)_2$, -$CH{=}NR_7$, -NR_7OH, -OR_7, -$C(O)R_7$, -$OC(O)R_7$, or -$OC(O)OR_7$;

each R_{14} is independently –H, -(C_1-C_6)alkyl, -(C_2-C_6)alkenyl, -(C_2-C_6)alkynyl, -(C_3-C_8)cycloalkyl, -(C_5-C_8)cycloalkenyl, -(C_1-C_6)alkoxy-(C_1-C_6)alkyl, -phenyl, -$C(halo)_3$, -$CH(halo)_2$, -$CH_2(halo)$, -(3- to 7-membered)heterocycle, -(C_1-C_6)haloalkyl, -(C_2-C_6)haloalkenyl, -(C_2-C_6)haloalkynyl, -(C_2-C_6)hydroxyalkenyl, -(C_2-C_6)hydroxyalkynyl, -(C_1-C_6)alkoxy(C_2-C_6)alkyl, -(C_1-C_6)alkoxy(C_2-C_6)alkenyl, -(C_1-C_6)alkoxy(C_2-C_6)alkynyl, -(C_1-C_6)alkoxy(C_3-C_8)cycloalkyl, -CN, -OH, -halo, -$OC(halo)_3$, -N_3, -NO_2, -$CH{=}NR_7$, -$N(R_7)_2$, -NR_7OH, -OR_7, -SR_7, -$O(CH_2)_bOR_7$, -$O(CH_2)_bSR_7$, -$O(CH_2)_bN(R_7)_2$, -$N(R_7)(CH_2)_bOR_7$, -$N(R_7)(CH_2)_bSR_7$, -$N(R_7)(CH_2)_bN(R_7)_2$, -$N(R_7)COR_7$, -$C(O)R_7$, -$C(O)OR_7$, -$OC(O)R_7$,

-OC(O)OR$_7$, -S(O)R$_7$, or -S(O)$_2$R$_7$, -S(O)$_2$N(R$_7$)$_2$, -SO$_2$C(halo)$_3$, -SO$_2$(3- to 7-membered)heterocycle, -CON(R$_7$)$_2$, -(C$_1$-C$_5$)alkyl-C=NOR$_7$, -(C$_1$-C$_5$)alkyl-C(O)-N(R$_7$)$_2$, -(C$_1$-C$_6$)alkyl-NHSO$_2$N(R$_7$)$_2$, or –(C$_1$-C$_6$)alkyl-C(=NH)-N(R$_7$)$_2$;

each R$_{20}$ is independently –H, -(C$_1$-C$_6$)alkyl, or -(C$_3$-C$_8$)cycloalkyl;
each R$_{21}$ is independently –H, -(C$_1$-C$_6$)alkyl,



;

each halo is independently -F, -Cl, -Br, or -I;
n is the integer 1, 2, or 3;
p is the integer 1 or 2;
each b is independently 1 or 2;
q is the integer 0, 1, 2, 3 or 4;
r is the integer 0, 1, 2, 3, 4, 5, or 6;
s is the integer 0, 1, 2, 3, 4, or 5;
t is the integer 0, 1, 2, or 3; and
m is the integer 0, 1, or 2.

2. The compound of claim 1, wherein X = O.

3. The compound according to any one of claims 1 to 2, wherein R$_4$ is halo.


4. The compound according to any one of claims 1 to 3, wherein R$_1$ is halo.

5. The compound according to any one of claims 1 to 4, wherein W is C and the dashed line is absent.

6. The compound according to any one of claims 1 to 4, wherein W is C, and the dashed line is a double bond.

7. The compound according to any one of claims 1 to 4, wherein W is N, R_4 is absent and the dashed line is absent.

8. A compound according to any one of claims 1 to 7, wherein Ar_1 is




9. The compound according to any one of claims 1 to 8, wherein for compounds according to formula I J is selected from OR_{20} or $-N(R_{20})_2$.


10. The compound of any one of claims 1 to 9, wherein for compounds according to formula I R_{20} is selected from H or $-(C_1\text{-}C_6)$alkyl.

11. The compound according to any one of claims 1 to 10, wherein for compounds according to formula I Z_3 is independently selected from H or $(C_1\text{-}C_6)$alkyl.

12. The compound according to any one of claims 1 to 11, wherein for compounds according to formula I Ar_2 is




13. The compound according to any one of claims 1 to 12, wherein for compounds according to formula I Ar_2 is



14. The compound according to any one of claims 1 to 13, wherein for compounds according to formula I halo is F or Cl.

15. The compound according to any one of claims 1 to 14, wherein for compounds according to formula I s or q is 1 or 2.

16. The compound according to any one of claims 1 to 11, wherein for compounds according to formula I Ar_2 is



17. The compound according to any one of claims 1to 15, wherein for compounds according to formula I Ar_2 is 2-pyridyl or phenyl, s or q is 1 and the R_{14} substituent is in the 4-position of the Ar_2-substituent.


18. The compound according to any one of claims 1 to 15, wherein for compounds according to formula I Ar_2 is 2-pyridyl or phenyl, s or q is 2 and the R_{14} substituent is in the 3- and 4-position of the Ar_2-substituent.

19. The compound according to any one of the preceding claims, wherein m = 0.

20. The compound according to any one of claims 1 to 18, wherein m = 1 and preferably R_3 is $(C_1$-$C_6)$alkyl.


21. The compound according to any one of the preceding claims, wherein Ar_2 is

a)




; or

b)




wherein R_{14} is selected from –H, -Cl, -F, -Br, $-OCF_3$, $-(C_1-C_6)$alkyl, SO_2CF_3, $SO_2(C_1-C_6)$alkyl, $-OCH_3$, $-OCH_2CH_3$ or $-OCH(CH_3)_2$, or

c)



wherein $R_{14'}$ is selected from –H, -Cl, -F, -Br, $-CF_3$, $-OCF_3$, $-(C_1-C_6)$alkyl, SO_2CF_3, $SO_2(C_1-C_6)$alkyl, $-OCH_3$, $-OCH_2CH_3$ or $-OCH(CH_3)_2$,
or


d)



,


wherein $R_{14'}$ is selected from –H, -Cl, -F, -Br, -CF_3, -OCF_3, -(C_1-C_6)alkyl, SO_2CF_3, SO_2(C_1-C_6)alkyl, -OCH_3, -OCH_2CH_3, -$OCH(CH_3)_2$; or

e)



; or

f)



wherein each R_8 and R_9 is independently -H, -Cl, -Br, -F, $-CH_3$, $-OCH_3$, $-OCH_2CH_3$, $-CF_3$, $-OCF_3$, *iso*-propyl, or *tert*-butyl.

22. A compound of any one of the preceding claims, wherein the pharmaceutically acceptable derivative is a pharmaceutically acceptable salt.

23. A composition comprising a compound of any one of claims 1 to 21 or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier or excipient.

24. A method of inhibiting TRPV1 function in a cell comprising contacting a cell capable of expressing TRPV1 with an effective amount of a compound of any one of claims 1 to 21 or a pharmaceutically acceptable derivative thereof.

25. A use of a compound or a pharmaceutically acceptable derivative thereof according to any one of claims 1 to 21 in the production of a medicament for the treatment or prevention of pain, UI, an ulcer, IBD, or IBS in an animal.